CD70-targeted immunoPET Imaging of Kidney Cancer

Launched by RENJI HOSPITAL · Nov 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging method called \[18F\]RCCB6 PET/CT to help diagnose kidney cancer, particularly a type known as clear cell renal cell carcinoma. The goal is to see how effectively this imaging technique can identify kidney tumors and understand how the imaging agent behaves in the body. By improving the way we can visualize kidney cancer, doctors hope to make better treatment decisions for patients.

To participate in this study, individuals need to be between 18 and 80 years old and have a confirmed diagnosis of kidney cancer or a suspicion of it based on previous imaging tests. Participants will need to provide consent to take part in the trial and follow specific guidelines. However, individuals who are pregnant, have severe liver or kidney problems, have had major surgery in the past month, or are allergic to certain types of radiopharmaceuticals cannot join the study. Those who do participate can expect to undergo the new imaging tests and help contribute to important research that may improve kidney cancer diagnosis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 18-80 year-old and of either sex；
• • 2. Histologically confirmed diagnosis of kidney cancer (especially clear cell renal cell carcinoma and papillary renal cell carcinoma) or suspected kidney cancer by diagnostic imaging;
• • 3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
• Exclusion Criteria:
• • 1. Pregnancy；
• • 2. Severe hepatic and renal insufficiency;
• • 3. History of serious surgery in the last month;
• • 4. Allergic to antibody or single-domain antibody radiopharmaceuticals.